Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...

Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Lastly, the company’s dividend looks well-covered with a payout ratio of under 50%. Novo Nordisk Is a Long-term Winner Despite the recent setback, Novo Nordisk is a long-term winner.

The experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7 percent in a late-stage trial, Reuters quoted Novo Nordisk as saying on Friday ...

executive vice president for development at Novo Nordisk, said in a company news release Friday. He said Novo Nordisk would use insights from the trial “to further explore the additional weight ...